Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCytomX Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.11 | -$0.02 | -$0.07 |
| Q2 2025 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q3 2025 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q4 2025 | 1 | -$0.15 | -$0.15 | -$0.15 |
| Q1 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q2 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q4 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
CytomX Therapeutics, Inc. Earnings Date And Information
CytomX Therapeutics, Inc. last posted its earnings results on Thursday, March 6th, 2025. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.2 by $0.42. The company had revenue of 38.09 M for the quarter and had revenue of 138.10 M for the year. CytomX Therapeutics, Inc. has generated $0 earnings per share over the last year ($0.38 diluted earnings per share) and currently has a price-to-earnings ratio of 1.54. CytomX Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based on prior year's report dates.
CytomX Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/06/2025 | Q4 2024 | -$0.20 | $0.22 | 0.42 | $13.04 M | $38.09 M |
| 11/07/2024 | Q3 2024 | -$0.17 | $0.07 | 0.24 | $17.10 M | $33.43 M |
| 08/08/2024 | Q2 2024 | -$0.07 | -$0.08 | -0.01 | $20.00 M | $25.12 M |
| 05/08/2024 | Q1 2024 | -$0.08 | $0.17 | 0.25 | N/A | $41.46 M |
| 03/11/2024 | Q4 2023 | $0.00 | $0.01 | 0.01 | $19.60 M | $26.61 M |
| 11/07/2023 | Q3 2023 | -$0.19 | $0.04 | 0.23 | $13.34 M | $26.38 M |
| 08/08/2023 | Q2 2023 | -$0.19 | -$0.02 | 0.17 | $13.68 M | $24.72 M |
| 05/09/2023 | Q1 2023 | -$0.16 | -$0.01 | 0.15 | N/A | $23.50 M |
| 03/27/2023 | Q4 2022 | -$0.21 | -$0.40 | -0.19 | N/A | $946,000 |
| 11/08/2022 | Q3 2022 | -$0.32 | -$0.34 | -0.02 | $18.15 M | $16.92 M |
| 08/04/2022 | Q2 2022 | -$0.36 | -$0.36 | 0 | $18.11 M | $18.17 M |
| 05/05/2022 | Q1 2022 | -$0.35 | -$0.36 | -0.01 | N/A | $17.14 M |
| 03/01/2022 | Q4 2021 | -$0.25 | -$0.40 | -0.15 | N/A | $19.73 M |
| 11/04/2021 | Q3 2021 | -$0.30 | -$0.35 | -0.05 | $18.38 M | $17.59 M |
| 08/05/2021 | Q2 2021 | -$0.26 | -$0.30 | -0.04 | $16.96 M | $16.29 M |
| 05/06/2021 | Q1 2021 | -$0.29 | -$0.26 | 0.03 | N/A | $15.97 M |
| 02/24/2021 | Q4 2020 | -$0.35 | -$0.32 | 0.03 | N/A | $16.37 M |
| 11/05/2020 | Q3 2020 | -$0.36 | -$0.32 | 0.04 | $17.14 M | $17.79 M |
| 08/06/2020 | Q2 2020 | $0.34 | -$0.34 | -0.68 | $52.99 M | $16.61 M |
| 05/07/2020 | Q1 2020 | -$0.46 | $0.27 | 0.73 | N/A | $49.59 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
CytomX Therapeutics, Inc. Earnings: FAQ's
CytomX Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based offlast year's report dates.
In the previous quarter, CytomX Therapeutics, Inc. (:CTMX) reported $0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.2 by $0.42.
The conference call for CytomX Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for CytomX Therapeutics, Inc.'s latest earnings report can be read online.
CytomX Therapeutics, Inc. (:CTMX) has a recorded annual revenue of $138.10 M.
CytomX Therapeutics, Inc. (:CTMX) has a recorded net income of $31.87 M.CytomX Therapeutics, Inc. has generated $0.38 earnings per share over the last four quarters.
CytomX Therapeutics, Inc. (:CTMX) has a price-to-earnings ratio of 1.54 and price/earnings-to-growth ratio is 0.01.